Related references
Note: Only part of the references are listed.CAR T cell therapies for patients with multiple myeloma
Lekha Mikkilineni et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
BCMA-targeted immunotherapy for multiple myeloma
Bo Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
Sabrina Trudel et al.
ANNALS OF HEMATOLOGY (2019)
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
Cinnie Yentia Soekojo et al.
BLOOD CANCER JOURNAL (2019)
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
Efstathios Kastritis et al.
BLOOD ADVANCES (2019)
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet et al.
BLOOD (2018)
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
Jin Lu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience
Nicola Maciocia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
S. Lonial et al.
LEUKEMIA (2016)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Rachid C. Baz et al.
BLOOD (2016)
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Silvia Park et al.
ANNALS OF HEMATOLOGY (2014)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Peter H. O'Donnell et al.
CLINICAL CANCER RESEARCH (2009)
Share Paper
